Esperion Therapeutics(ESPR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ESPR Esperion Therapeutics

Post-Mkt 03-26 19:04:37 EDT

2.85

+0.09

+3.26%

盘后2.85

+0.00+0.02%

17:39 EDT

High2.89	Low2.66	Vol3.96M
Open2.71	D1 Closing2.76	Amplitude8.33%
Mkt Cap731.91M	Tradable Cap675.45M	Total Shares256.81M
T/O11.19M	T/O Rate1.67%	Tradable Shares237.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ESPR","market":"US","secType":"STK","nameCN":"Esperion Therapeutics","latestPrice":2.85,"timestamp":1774555200000,"preClose":2.76,"halted":0,"volume":3957109,"hourTrading":{"tag":"盘后","latestPrice":2.8505,"preClose":2.85,"latestTime":"17:39 EDT","volume":21804,"amount":62141.748864,"timestamp":1774561186624,"change":0.0005,"changeRate":0.000175,"amplitude":0.003509},"delay":0,"changeRate":0.03260869565217402,"floatShares":237000000,"shares":256810500,"eps":-0.109118,"marketStatus":"Post-Mkt","change":0.09,"latestTime":"03-26 19:04:37 EDT","open":2.705,"high":2.89,"low":2.66,"amount":11192050.856192699,"amplitude":0.083333,"askPrice":2.9,"askSize":100,"bidPrice":2.81,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-0.109118,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1774569600000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1372219200000,"exchange":"NASDAQ","adjPreClose":2.76,"preHourTrading":{"tag":"盘前","latestPrice":2.7,"preClose":2.76,"latestTime":"09:28 EDT","volume":1213,"amount":3426.270125,"timestamp":1774531706060,"change":-0.06,"changeRate":-0.021739,"amplitude":0.021739},"postHourTrading":{"tag":"盘后","latestPrice":2.8505,"preClose":2.85,"latestTime":"17:39 EDT","volume":21804,"amount":62141.748864,"timestamp":1774561186624,"change":0.0005,"changeRate":0.000175,"amplitude":0.003509},"volumeRatio":0.899809,"impliedVol":0.6361,"impliedVolPercentile":0.2908},"requestUrl":"/m/hq/s/ESPR/wiki","defaultTab":"wiki","newsList":[{"id":"2620422421","title":"Get an Lp(a) test - and 3 other things you must do now for heart health","url":"https://stock-news.laohu8.com/highlight/detail?id=2620422421","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620422421?lang=en_us&edition=fundamental","pubTime":"2026-03-19 23:29","pubTimestamp":1773934140,"startTime":"0","endTime":"0","summary":"I'm a cardiologist. Here are the most important new guidelines that younger people need to know about when it comes to their heart health.Physicians are now urging younger adults to get screened for heart disease.We have all seen the headlines about deaths from heart disease rising in younger people.This has prompted many of us in preventive cardiology to question how well cardiovascular disease prevention is working if mortality is so high. How should we tackle the expected rise in heart disease in women and men?There are now new guidelines, which were published Friday by the American College of Cardiology and the American Heart Association, that will change how we think about cardiovascular disease prevention - and specifically cholesterol. We already know that lifetime exposure to high LDL, or low-density lipoprotein, increases cardiovascular risk, and that getting care earlier can help prevent heart disease. That's where the focus of cardiovascular care really needs to be.Low-densi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0882574055.USD","LU2242652126.USD","LU2089984988.USD","LU2362541513.USD","LU0053666078.USD","LU0122379950.USD","LU2362541273.HKD","BK4566","LU0320765992.SGD","LU0823416689.USD","LU0823434583.USD","LU0114720955.EUR","IE00BFTCPJ56.SGD","LU1023059063.AUD","REGN","IE00B2B36J28.USD","LU2362540622.SGD","BK4007","IE0009355771.USD","ESPR","LU0889565916.HKD","LU0868494617.USD","LU0823434740.USD","LU1974910355.USD","BK4585","LU1057294990.SGD","IE00BJJMRZ35.SGD","LU2023250504.SGD","LU2468319806.SGD","LU1917777945.USD","IE00BJT1NW94.SGD","BK4581","AMGN","BK4533","LU2112291526.USD","LU0109394709.USD","LU0058720904.USD","LU2106854487.HKD","LU1983299246.USD","LU2242646821.SGD","LU1571399168.USD","BK4588","SG9999001440.SGD","IE00B4R5TH58.HKD","BK4599","IE0002141913.USD","LU1061106388.HKD","BK4534","LU2237438978.USD","LU0289739699.SGD"],"gpt_icon":0},{"id":"2620421040","title":"Esperion to present two CLEAR Outcomes analyses at ACC 2026 Annual Scientific Session","url":"https://stock-news.laohu8.com/highlight/detail?id=2620421040","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620421040?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:03","pubTimestamp":1773749011,"startTime":"0","endTime":"0","summary":"Esperion will attend the American College of Cardiology 2026 Annual Scientific Session  in New Orleans on March 28-30, 2026. Esperion plans to present an analysis on bempedoic acid and stroke incidence on March 28, 2026. It also plans to present an analysis on cardiovascular outcomes in patients with autoimmune or inflammatory diseases on March 29, 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL2rYvFW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","SG9999014021.USD","SG9999014039.USD","BK4112","LU0314104364.USD","ESPR","IE00BKPKM429.USD","IE00BGHQF748.EUR","SG9999014013.SGD","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","IE00B64PRP62.GBP","LU2095319765.USD","BK4588","SG9999014005.SGD","IE00BN0W2V16.EUR","NDAQ","BK4007","IE00BN0W2T93.GBP","BK4585","LU2210149790.SGD"],"gpt_icon":0},{"id":"2619452993","title":"Esperion says bempedoic acid receives recommendations in ACC/AHA Guideline","url":"https://stock-news.laohu8.com/highlight/detail?id=2619452993","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619452993?lang=en_us&edition=fundamental","pubTime":"2026-03-16 18:51","pubTimestamp":1773658305,"startTime":"0","endTime":"0","summary":"Esperion (ESPR) welcomed the inclusion of bempedoic acid for LDL-C lowering and cardiovascular risk reduction in the 2026 Americal College of Cardi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/esperion-says-bempedoic-acid-receives-recommendations-in-acc-aha-guideline-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/esperion-says-bempedoic-acid-receives-recommendations-in-acc-aha-guideline-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ESPR","BK4007"],"gpt_icon":0},{"id":"2619454364","title":"Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2619454364","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619454364?lang=en_us&edition=fundamental","pubTime":"2026-03-16 18:30","pubTimestamp":1773657000,"startTime":"0","endTime":"0","summary":"– Bempedoic Acid Receives Strongest Endorsement from AHA/ACC Multisociety Guideline for Patients with Statin Intolerance and in Primary and Secondary Prevention Patients with Severe Hypercholesterolem","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/16/3256088/0/en/Esperion-s-Bempedoic-Acid-Receives-Multiple-Class-1-Recommendations-in-2026-ACC-AHA-Multisociety-Guideline-for-Management-of-Dyslipidemia.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAC","ESPR","BK4007","BK4211"],"gpt_icon":0},{"id":"2619991196","title":"Esperion Therapeutics Is Maintained at Market Outperform by Citizens","url":"https://stock-news.laohu8.com/highlight/detail?id=2619991196","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619991196?lang=en_us&edition=fundamental","pubTime":"2026-03-13 18:45","pubTimestamp":1773398700,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ESPR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 13, 2026 06:45 ET (10:45 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESPR"],"gpt_icon":0},{"id":"2619198782","title":"Esperion price target raised to $5 from $4 at Citizens","url":"https://stock-news.laohu8.com/highlight/detail?id=2619198782","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619198782?lang=en_us&edition=fundamental","pubTime":"2026-03-13 17:36","pubTimestamp":1773394580,"startTime":"0","endTime":"0","summary":"Citizens raised the firm’s price target on Esperion (ESPR) to $5 from $4 and keeps an Outperform rating on the shares. Esperion reported Q4 results...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/esperion-price-target-raised-to-5-from-4-at-citizens-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/esperion-price-target-raised-to-5-from-4-at-citizens-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ESPR","BK4007"],"gpt_icon":0},{"id":"2619591153","title":"HLS Therapeutics Inc. publishes 2026 annual report","url":"https://stock-news.laohu8.com/highlight/detail?id=2619591153","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619591153?lang=en_us&edition=fundamental","pubTime":"2026-03-13 00:16","pubTimestamp":1773332193,"startTime":"0","endTime":"0","summary":"HLS published its annual report outlining continued focus on specialty CNS and cardiovascular products, led by Clozaril in Canada and the U.S. and Vascepa in Canada. The company entered a new credit agreement in 2025 that replaced its prior facility and extended maturity to 2029, with total facilities of CAD 107 million. HLS also licensed Canadian rights to Nilemdo and Nexlizet from Esperion, paying an upfront fee of USD 1 million. Health Canada approved Nilemdo in November 2025, while Nexlizet received a Notice of Non-Compliance and is targeted for resolution in Q4 2026 ahead of a planned 2027 launch. In 2024, HLS sold its Xenpozyme royalty interest to DRI in a transaction valued at up to USD 45.75 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investmen","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nNDL1YbxNg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESPR","BK4007"],"gpt_icon":0},{"id":"2618009907","title":"Esperion Therapeutics Flags Material Weakness in Financial Controls, Raising Reporting and Regulatory Risks","url":"https://stock-news.laohu8.com/highlight/detail?id=2618009907","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618009907?lang=en_us&edition=fundamental","pubTime":"2026-03-12 14:01","pubTimestamp":1773295286,"startTime":"0","endTime":"0","summary":"Esperion Therapeutics (ESPR) has disclosed a new risk, in the Accounting & Financial Operations category. Esperion Therapeutics faces heightened re...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/esperion-therapeutics-flags-material-weakness-in-financial-controls-raising-reporting-and-regulatory-risks?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/esperion-therapeutics-flags-material-weakness-in-financial-controls-raising-reporting-and-regulatory-risks?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ESPR","BK4007"],"gpt_icon":0},{"id":"2618694968","title":"Piper Sandler Sticks to Their Buy Rating for Esperion (ESPR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618694968","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618694968?lang=en_us&edition=fundamental","pubTime":"2026-03-11 18:57","pubTimestamp":1773226669,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst David Amsellem reiterated a Buy rating on Esperion today and set a price target of $9.00. According to TipRanks, Amsellem is ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/piper-sandler-sticks-to-their-buy-rating-for-esperion-espr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/piper-sandler-sticks-to-their-buy-rating-for-esperion-espr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ESPR"],"gpt_icon":0},{"id":"2618540329","title":"Esperion Therapeutics: Strong 2025 Execution, Expanding Cardiometabolic Platform, and Vision 2040 Underpin Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2618540329","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618540329?lang=en_us&edition=fundamental","pubTime":"2026-03-10 23:35","pubTimestamp":1773156931,"startTime":"0","endTime":"0","summary":"In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Esperion, with a price target of $16.00. Joseph Pantgi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/esperion-therapeutics-strong-2025-execution-expanding-cardiometabolic-platform-and-vision-2040-underpin-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/esperion-therapeutics-strong-2025-execution-expanding-cardiometabolic-platform-and-vision-2040-underpin-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ESPR"],"gpt_icon":0},{"id":"2618516359","title":"BUZZ-Esperion falls after quarterly results miss estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2618516359","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618516359?lang=en_us&edition=fundamental","pubTime":"2026-03-10 22:42","pubTimestamp":1773153749,"startTime":"0","endTime":"0","summary":"BUZZ-Esperion falls after quarterly results miss estimates** Shares of drug developer Esperion Therapeutics ESPR.O fall 4.61% to $2.90** Co posts Q4 adjusted profit of 22 cents per share, compared to analysts' estimate of 24 cents per share, according to data compiled by LSEG ** Posts Q4 revenue of $168.4 million, missing analysts' estimate of $174.5 million ** ESPR shares down 22% YTD after having risen over 68% in 2025","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nL4N3ZY0R7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESPR","BK4007"],"gpt_icon":0},{"id":"2618955154","title":"Esperion Therapeutics Shares Gain 2.5% After Co Swings to Q4 Profit","url":"https://stock-news.laohu8.com/highlight/detail?id=2618955154","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618955154?lang=en_us&edition=fundamental","pubTime":"2026-03-10 21:31","pubTimestamp":1773149475,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nL4N3ZY17V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ESPR","BK4007"],"gpt_icon":0},{"id":"2618493930","title":"Shares of Esperion Therapeutics up 7.5% Premarket After Co Swings to Q4 Profit","url":"https://stock-news.laohu8.com/highlight/detail?id=2618493930","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618493930?lang=en_us&edition=fundamental","pubTime":"2026-03-10 20:17","pubTimestamp":1773145077,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nL4N3ZY12Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ESPR","BK4007"],"gpt_icon":0},{"id":"2618820939","title":"Esperion Therapeutics Q4 revenue jumps 144% on US product strength","url":"https://stock-news.laohu8.com/highlight/detail?id=2618820939","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618820939?lang=en_us&edition=fundamental","pubTime":"2026-03-10 18:11","pubTimestamp":1773137461,"startTime":"0","endTime":"0","summary":"Esperion Therapeutics Q4 revenue jumps 144% on US product strengthOverviewBiopharmaceutical firm's Q4 total revenue grew 144% yr/yr to $168.4 mlnNet income for Q4 missed analyst expectationsCompany to","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nL1N3ZY0CV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESPR","BK4007"],"gpt_icon":0},{"id":"2618936712","title":"Earnings Flash (ESPR) Esperion Therapeutics Posts Q4 EPS $0.22, vs. FactSet Est of $0.27","url":"https://stock-news.laohu8.com/highlight/detail?id=2618936712","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618936712?lang=en_us&edition=fundamental","pubTime":"2026-03-10 18:04","pubTimestamp":1773137067,"startTime":"0","endTime":"0","summary":"Earnings Flash (ESPR) Esperion Therapeutics Posts Q4 EPS $0.22, vs. FactSet Est of $0.27","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ESPR"],"gpt_icon":0},{"id":"2618893644","title":"Esperion Therapeutics Q4 EPS $0.22 Misses $0.30 Estimate, Sales $168.446M Miss $174.519M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2618893644","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618893644?lang=en_us&edition=fundamental","pubTime":"2026-03-10 18:01","pubTimestamp":1773136894,"startTime":"0","endTime":"0","summary":"Esperion Therapeutics (NASDAQ:ESPR) reported quarterly earnings of $0.22 per share which missed the analyst consensus estimate of $0.30 by 25.68 percent. This is a 300 percent increase over losses of $(0.11) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51150583/esperion-therapeutics-q4-eps-0-22-misses-0-30-estimate-sales-168-446m-miss-174-519m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESPR"],"gpt_icon":0},{"id":"2618364529","title":"BRIEF-Esperion Therapeutics Q4 Product Sales USD 43.723 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2618364529","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618364529?lang=en_us&edition=fundamental","pubTime":"2026-03-10 18:00","pubTimestamp":1773136846,"startTime":"0","endTime":"0","summary":"Mar 10  - Esperion Therapeutics Q4 net income USD 61.831 million vs. IBES estimate USD 70 million.Q4 operating income USD 85.233 million vs. IBES estimate USD 98.7 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nPLXFF905F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ESPR"],"gpt_icon":0},{"id":"2618936482","title":"Esperion Therapeutics Q4 Operating Expenses USD 83.213 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2618936482","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618936482?lang=en_us&edition=fundamental","pubTime":"2026-03-10 18:00","pubTimestamp":1773136802,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nPLXFF905F:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ESPR","BK4007"],"gpt_icon":0},{"id":"2618936432","title":"Esperion Therapeutics Q4 Operating Income USD 85.233 Million VS. Ibes Estimate USD 98.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2618936432","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618936432?lang=en_us&edition=fundamental","pubTime":"2026-03-10 18:00","pubTimestamp":1773136802,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nPLXFF905F:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ESPR","BK4007"],"gpt_icon":0},{"id":"2618898939","title":"Esperion Therapeutics Inc - Expects FY2026 Operating Expenses of $225 Mln-$255 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2618898939","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618898939?lang=en_us&edition=fundamental","pubTime":"2026-03-10 18:00","pubTimestamp":1773136802,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nPLXFF905F:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ESPR"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.esperion.com","stockEarnings":[{"period":"1week","weight":0.1018},{"period":"1month","weight":-0.1737},{"period":"3month","weight":-0.3013},{"period":"6month","weight":0.0415},{"period":"1year","weight":0.6429},{"period":"ytd","weight":-0.2541}],"compareEarnings":[{"period":"1week","weight":-0.007},{"period":"1month","weight":-0.0375},{"period":"3month","weight":-0.0486},{"period":"6month","weight":-0.0076},{"period":"1year","weight":0.1414},{"period":"ytd","weight":-0.0368}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.","yearOnYearQuotes":[{"month":1,"riseRate":0.461538,"avgChangeRate":-0.043403},{"month":2,"riseRate":0.461538,"avgChangeRate":0.113863},{"month":3,"riseRate":0.461538,"avgChangeRate":-0.039269},{"month":4,"riseRate":0.416667,"avgChangeRate":-0.028114},{"month":5,"riseRate":0.666667,"avgChangeRate":-0.032489},{"month":6,"riseRate":0.75,"avgChangeRate":0.035061},{"month":7,"riseRate":0.461538,"avgChangeRate":-0.001019},{"month":8,"riseRate":0.461538,"avgChangeRate":0.026549},{"month":9,"riseRate":0.538462,"avgChangeRate":-0.000828},{"month":10,"riseRate":0.538462,"avgChangeRate":-0.017419},{"month":11,"riseRate":0.692308,"avgChangeRate":0.148542},{"month":12,"riseRate":0.461538,"avgChangeRate":0.067177}],"exchange":"NASDAQ","name":"Esperion Therapeutics","nameEN":"Esperion Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Esperion Therapeutics(ESPR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Esperion Therapeutics(ESPR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Esperion Therapeutics,ESPR,Esperion Therapeutics股票,Esperion Therapeutics股票老虎,Esperion Therapeutics股票老虎国际,Esperion Therapeutics行情,Esperion Therapeutics股票行情,Esperion Therapeutics股价,Esperion Therapeutics股市,Esperion Therapeutics股票价格,Esperion Therapeutics股票交易,Esperion Therapeutics股票购买,Esperion Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Esperion Therapeutics(ESPR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Esperion Therapeutics(ESPR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction